Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy

NCT03007407 is registered in ClinicalTrials.gov with NSABP Foundation Inc as lead sponsor.

NCT NCT03007407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03007407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy
Lead sponsor
NSABP Foundation Inc
Phase
Phase 2
Overall status
Completed
Start date
July 31, 2017
Completion date
August 9, 2019
Enrollment
33 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer metastatic